AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2017
Jul 5, 2017
35334_dirs_2017-07-05_b210e99c-7084-4bda-b729-567fc65b429e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2017-06-30
Reporting Person: Pascale Adam (CFO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-06-30 | Options to buy Common Stock | $0.49 | A | 4738 | Acquired | 2027-06-30 | Common Stock (4738) | Direct |
Footnotes
F1: This option is being issued in exchange for a voluntary 20% deduction in salary.